M
At Myeloid, we have applied our extensive knowledge of advanced gene and cell therapies to build novel platform technologies that harness the innate abilities of myeloid cells. We have translated the learnings from our backgrounds and novel platform to create a clinical-stage, mRNA-immunotherapy pipeline focused on breakthrough therapies for cancer. We invite you to join us on this journey – patients are waiting.
Investor insights
Funding rounds participated in
$73M sweet spot round size
Investor type
Privately Held
Basic info
Industry
Biotechnology
Sectors
Biotechnology
Funding rounds raised
Total raised
$73M
from 2 investors over 1 rounds
M
Myeloid Therapeutics raised $73M on June 18, 2023
Investors: Hatteras Venture Partners and + 4 Other investors